FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2963742674> ?p ?o ?g. }

• W2963742674 endingPage "932" @default.
• W2963742674 startingPage "932" @default.
• W2963742674 abstract "<h3>Importance</h3> Chemotherapy is the recommended induction strategy in borderline resectable and locally advanced pancreatic ductal adenocarcinoma. However, the associated results on an intention-to-treat basis are poorly understood. <h3>Objective</h3> To investigate pragmatically the treatment compliance, conversion to surgery, and survival outcomes of patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma undergoing primary chemotherapy. <h3>Design, Setting, and Participants</h3> This prospective study took place in a national referral center for pancreatic diseases in Italy. Consecutive patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma were enrolled at the time of diagnosis (January 2013 through December 2015) and followed up to June 2018. <h3>Exposures</h3> The chemotherapy regimen, assigned based on multidisciplinary evaluation, was delivered either at a hub center or at spoke centers. By convention, primary chemotherapy was considered completed after 6 months. After restaging, surgical candidates were selected based on radiologic and biochemical response. All surgeries were carried out at the hub center. <h3>Main Outcomes and Measures</h3> Rates of receipt and completion of chemotherapy, rates of conversion to surgery, and disease-specific survival. <h3>Results</h3> Of 680 patients, 267 (39.3%) had borderline resectable and 413 (60.7%) had locally advanced pancreatic ductal adenocarcinoma. Overall, 66 patients (9.7%) were lost to follow-up. The rate of chemotherapy receipt was 92.9% (n = 570). The chemotherapeutic regimens most commonly used included FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) (260 [45.6%]) and gemcitabine plus nanoparticle albumin-bound–paclitaxel (123 [21.6%]). Nineteen patients (3.3%) receiving chemotherapy died within 6 months, mainly for disease progression. The treatment completion rate was 71.6% (408 of 570). The overall rate of resection was 15.1% (93 of 614) (borderline resectable, 60 of 249 [24.1%]; locally advanced, 33 of 365 [9%]; resection:exploration ratio, 63.3%). Independent predictors of resection were age, borderline resectable disease, chemotherapy completion, radiologic response, and biochemical response. The median survival for the whole cohort was 12.8 (95% CI, 11.7-13.9) months. Factors independently associated with survival were completion of chemotherapy, receipt of complementary radiation therapy, and resection. In patients who underwent resection, the median survival was 35.4 (95% CI, 27.0-43.7) months for initially borderline resectable and 41.8 (95% CI, 27.5-56.1) months for initially locally advanced disease. No pretreatment and posttreatment factors were associated with survival after pancreatectomy. <h3>Conclusions and Relevance</h3> This pragmatic observational cohort study with an intention-to-treat design provides real-world evidence of outcomes associated with the most current primary chemotherapy regimens used for borderline resectable and locally advanced pancreatic ductal adenocarcinoma." @default.
• W2963742674 created "2019-07-30" @default.
• W2963742674 creator A5002957109 @default.
• W2963742674 creator A5007281247 @default.
• W2963742674 creator A5009250320 @default.
• W2963742674 creator A5009443291 @default.
• W2963742674 creator A5015807323 @default.
• W2963742674 creator A5016906180 @default.
• W2963742674 creator A5023308842 @default.
• W2963742674 creator A5025062457 @default.
• W2963742674 creator A5029679816 @default.
• W2963742674 creator A5044714013 @default.
• W2963742674 creator A5047796715 @default.
• W2963742674 creator A5049680516 @default.
• W2963742674 creator A5052345863 @default.
• W2963742674 creator A5054911905 @default.
• W2963742674 creator A5055043306 @default.
• W2963742674 creator A5055751658 @default.
• W2963742674 creator A5056335013 @default.
• W2963742674 creator A5057818859 @default.
• W2963742674 creator A5058034886 @default.
• W2963742674 creator A5063135890 @default.
• W2963742674 creator A5071657406 @default.
• W2963742674 creator A5073612690 @default.
• W2963742674 creator A5074748035 @default.
• W2963742674 creator A5086805194 @default.
• W2963742674 date "2019-10-01" @default.
• W2963742674 modified "2023-09-27" @default.
• W2963742674 title "Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma" @default.
• W2963742674 cites W1955000909 @default.
• W2963742674 cites W1967508992 @default.
• W2963742674 cites W1994177577 @default.
• W2963742674 cites W2012005360 @default.
• W2963742674 cites W2013986156 @default.
• W2963742674 cites W2019607817 @default.
• W2963742674 cites W2022501291 @default.
• W2963742674 cites W2044211072 @default.
• W2963742674 cites W2081183739 @default.
• W2963742674 cites W2087484885 @default.
• W2963742674 cites W2151253787 @default.
• W2963742674 cites W2165480504 @default.
• W2963742674 cites W2195071101 @default.
• W2963742674 cites W2345822778 @default.
• W2963742674 cites W2413386818 @default.
• W2963742674 cites W2465801062 @default.
• W2963742674 cites W2467479187 @default.
• W2963742674 cites W2502134830 @default.
• W2963742674 cites W2520770744 @default.
• W2963742674 cites W2536439468 @default.
• W2963742674 cites W2559029437 @default.
• W2963742674 cites W2607175459 @default.
• W2963742674 cites W2751901379 @default.
• W2963742674 cites W2753033885 @default.
• W2963742674 cites W2772770935 @default.
• W2963742674 cites W2783374694 @default.
• W2963742674 cites W2799575632 @default.
• W2963742674 cites W2801077576 @default.
• W2963742674 cites W2802146467 @default.
• W2963742674 cites W2885486990 @default.
• W2963742674 cites W2891625981 @default.
• W2963742674 cites W2898193720 @default.
• W2963742674 cites W2912196744 @default.
• W2963742674 cites W4205565809 @default.
• W2963742674 doi "https://doi.org/10.1001/jamasurg.2019.2277" @default.
• W2963742674 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6659151" @default.
• W2963742674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31339530" @default.
• W2963742674 hasPublicationYear "2019" @default.
• W2963742674 type Work @default.
• W2963742674 sameAs 2963742674 @default.
• W2963742674 citedByCount "81" @default.
• W2963742674 countsByYear W29637426742019 @default.
• W2963742674 countsByYear W29637426742020 @default.
• W2963742674 countsByYear W29637426742021 @default.
• W2963742674 countsByYear W29637426742022 @default.
• W2963742674 countsByYear W29637426742023 @default.
• W2963742674 crossrefType "journal-article" @default.
• W2963742674 hasAuthorship W2963742674A5002957109 @default.
• W2963742674 hasAuthorship W2963742674A5007281247 @default.
• W2963742674 hasAuthorship W2963742674A5009250320 @default.
• W2963742674 hasAuthorship W2963742674A5009443291 @default.
• W2963742674 hasAuthorship W2963742674A5015807323 @default.
• W2963742674 hasAuthorship W2963742674A5016906180 @default.
• W2963742674 hasAuthorship W2963742674A5023308842 @default.
• W2963742674 hasAuthorship W2963742674A5025062457 @default.
• W2963742674 hasAuthorship W2963742674A5029679816 @default.
• W2963742674 hasAuthorship W2963742674A5044714013 @default.
• W2963742674 hasAuthorship W2963742674A5047796715 @default.
• W2963742674 hasAuthorship W2963742674A5049680516 @default.
• W2963742674 hasAuthorship W2963742674A5052345863 @default.
• W2963742674 hasAuthorship W2963742674A5054911905 @default.
• W2963742674 hasAuthorship W2963742674A5055043306 @default.
• W2963742674 hasAuthorship W2963742674A5055751658 @default.
• W2963742674 hasAuthorship W2963742674A5056335013 @default.
• W2963742674 hasAuthorship W2963742674A5057818859 @default.
• W2963742674 hasAuthorship W2963742674A5058034886 @default.
• W2963742674 hasAuthorship W2963742674A5063135890 @default.
• W2963742674 hasAuthorship W2963742674A5071657406 @default.
• W2963742674 hasAuthorship W2963742674A5073612690 @default.

• next